The ethics of placebo-controlled trials: Methodological justifications
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The use of placebo controls in clinical trials remains controversial. Ethical analysis and international ethical guidance permit the use of placebo controls in randomized trials when scientifically indicated in four cases: (1) when there is no proven effective treatment for the condition under study; (2) when withholding treatment poses negligible risks to participants; (3) when there are compelling methodological reasons for using placebo, and withholding treatment does not pose a risk of serious harm to participants; and, more controversially, (4) when there are compelling methodological reasons for using placebo, and the research is intended to develop interventions that can be implemented in the population from which trial participants are drawn, and the trial does not require participants to forgo treatment they would otherwise receive. The concept of methodological reasons is essential to assessing the ethics of placebo controls in these controversial last two cases. This article sets out key considerations relevant to considering whether methodological reasons for a placebo control are compelling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
What Makes Clinical Research in Developing Countries Ethical? The Benchmarks of Ethical Research
Emanuel, E. J., Wendler, D., Killen, J., & Grady, C. (2004) · The Journal of Infectious Diseases · doi:10.1086/381709 · Cited by 966
Self-citationCognitive Recovery in Socially Deprived Young Children: The Bucharest Early Intervention Project
Nelson, C. A., Zeanah, C. H., Fox, N. A., Marshall, P. J., Smyke, A. T., & Guthrie, D. (2007) · Science · doi:10.1126/science.1143921 · Cited by 951 · cited 4×
“The BEIP investigators established a foster care program in Bucharest and their results were anticipated by policy-makers who were interested in applying them in Romania [18].”
BackgroundInfluentialTemple, R., & Ellenberg, S. S. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-6-200009190-00014 · Cited by 871
The Ethics of Clinical Research in the Third World
Angell, M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709183371209 · Cited by 863 · cited 1×
“Critics argued that placebo usewas unnecessary to test the efficacy of short course AZT and that the trials represented an unethical “double standard” [8,9].”
BackgroundRid, A. (2012) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0b013e318247d124 · Cited by 13 · cited 1×
“The tight connection forged between the project and Romanian policy-makers suggests that this study had sufficient social value to justify its design [19].”
Background
Cited by
American College of Physicians Ethics Manual: Sixth Edition
Snyder, L., & for the American College of Physicians Ethics, P. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-1-201201031-00001 · Cited by 354
Leveraging ChatGPT to Aid Construction Hazard Recognition and Support Safety Education and Training
Uddin, S. M. J., Albert, A., Ovid, A., & Alsharef, A. (2023) · Sustainability · doi:10.3390/su15097121 · Cited by 158
Leroy, A., Naudet, F., Vaiva, G., Francis, A., Thomas, P., & Amad, A. (2018) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-017-0819-5 · Cited by 74
COVID-19 vaccine trial ethics once we have efficacious vaccines
Wendler, D., Ochoa, J., Millum, J., Grady, C., & Taylor, H. A. (2020) · Science · doi:10.1126/science.abf5084 · Cited by 50
Self-citation
Metadata
- Authors
- Millum, J., & Grady, C.
- Venue
- Contemporary Clinical Trials
- Publisher
- Elsevier BV
- Published
- 2013-11
- Volume
- 36
- Issue
- 2
- Pages
- 510-514
- ISSN
- 1551-7144 (ISSN-L)
- OpenAlex
- W1974170500
- Cited by
- 155
- References
- 6
- FWCI
- 3.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.